SCHEMBL2325459

SCHEMBL2325459

COP(=O)(CC(=O)c1cnn(Cc2ccccc2)c1C)OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.43
LMNA P02545 4/20 0.42
NPC1 O15118 3/20 0.42
TSHR P16473 2/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
POLB P06746 2/20 0.41
HPGD P15428 1/20 0.39
FPR1 P21462 1/20 0.39
NPBWR1 P48145 1/20 0.39
MAPK1 P28482 1/20 0.39
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2327199 0.84 ALDH1A1 (0.44) SMN1; SMN2KMT2AALDH1A1KDM4ELMNA
SCHEMBL2325464 0.82 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AALDH1A1KDM4ELMNA
SCHEMBL21332787 0.80 KMT2A (0.55) SMN1; SMN2KMT2AALDH1A1KDM4ELMNA
SCHEMBL1550333 0.80 MAPK1 (0.58) SMN1; SMN2ALDH1A1LMNANPC1MAPT
SCHEMBL21333079 0.79 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AALDH1A1KDM4ELMNA
SCHEMBL15176566 0.79 SMN1; SMN2 (0.60) SMN1; SMN2KMT2AALDH1A1KDM4ELMNA
SCHEMBL6052538 0.79 KMT2A (0.55) SMN1; SMN2KMT2AALDH1A1KDM4ELMNA
SCHEMBL14343976 0.77 MAPK1 (0.56) SMN1; SMN2KMT2AALDH1A1KDM4ELMNA
SCHEMBL2325474 0.76 KLKB1 (0.47) KMT2AALDH1A1LMNANPC1RAB9A
SCHEMBL21332805 0.76 SMN1; SMN2 (0.77) SMN1; SMN2KMT2AALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 SMN1; SMN2 2843/4885KMT2A 2891/4885ALDH1A1 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.